發(fā)布時(shí)間：2018-08-13 21:42

【摘要】：目的檢測核糖體S6蛋白激酶4(ribosomal S6 protein kinase 4,RSK4)、CD44和MMP-9在原發(fā)性腎細(xì)胞癌(primary renal cell carcinoma,pRCC)及轉(zhuǎn)移性腎細(xì)胞癌(metastatic renal cell carcinoma,mRCC)中的表達(dá),探討三者表達(dá)水平及與臨床病理特征的相關(guān)性。方法采用免疫組化En Vision法檢測52例pRCC及48例mRCC中RSK4、MMP-9和CD44蛋白的表達(dá),并分析三者表達(dá)的相關(guān)性及與臨床病理特征的關(guān)系。結(jié)果 48例mRCC中RSK4、CD44及MMP-9的陽性率分別為75%(36/48)、68.75%(33/48)及91.7%(44/48),而三者在52例pRCC中的陽性率分別為44.2%(23/52)、34.6%(18/52)及69.2%(36/52)。RSK4、CD44及MMP-9在mRCC中的表達(dá)高于pRCC(PRSK4=0.002;PMMP-9=0.002;PCD44=0.001);RSK4、CD44及MMP-9表達(dá)與mRCC患者年齡、性別和腫瘤Fuhrman分級、轉(zhuǎn)移部位之間未見明確相關(guān)性(P0.05)。在mRCC中,三者之間的表達(dá)呈正相關(guān)(P=0.008);兩兩相關(guān)分析發(fā)現(xiàn)RSK4與CD44(P=0.019)、MMP-9與CD44(P=0.05)的表達(dá)之間存在正相關(guān),而RSK4與MMP-9(P=1.00)未見明確相關(guān)性。結(jié)論 RSK4、CD44及MMP-9在mRCC中的表達(dá)高于pRCC,提示三者可能介導(dǎo)腎細(xì)胞癌(renal cell carcinoma,RCC)的轉(zhuǎn)移,而其具體作用機(jī)制尚有待進(jìn)一步研究。
[Abstract]:Objective to detect the expression of ribosomal S6 protein kinase 4 (ribosomal S6 protein kinase 4) CD44 and MMP-9 in primary renal cell carcinoma (primary renal cell carcinoma pRCC) and metastatic renal cell carcinoma (metastatic renal cell carcinoma mRCC), and to explore the relationship between the expression of CD44 and MMP-9 and the clinicopathological features. Methods Immunohistochemical en Vision method was used to detect the expression of RSK4MMP 9 and CD44 in 52 cases of pRCC and 48 cases of mRCC, and the relationship between the expression of them and clinicopathological features was analyzed. 緇撴灉 48渚媘RCC涓璕SK4,CD44鍙?qiáng)MMP-9鐨勯槼鎬х巼鍒嗗埆涓，

本文編號：2182267